What Does Recent Data Related to SGLT2 Inhibitors Mean for My Patients? Effect of Online Medical Education on Physician Knowledge and Competence

Presentation Number: MON 613
Date of Presentation: April 3rd, 2017

Amy Larkin*1, Michael LaCouture2 and Anne Le1
1Medscape Education, 2Medscape Education, Mount Laurel, NJ



Busy clinicians find it challenging to stay up to date with new data, and the resulting knowledge gaps can lead to indecision and a lack of timely application of evidence-based therapies. We sought to determine if online continuing medical education (CME) could improve the clinical knowledge and competence of primary care physicians (PCPs) and diabetologists/endocrinologists (D/Es) regarding new data related to SGLT2 inhibitors.


The CME activity was developed as an online video roundtable discussion between 3 experts in T2D management. We assessed the effects of education using a 4-question linked pre-/post-assessment study design. McNemar’s chi-squared test was used to assess if the mean post‐assessment score differed from the mean pre‐assessment score. P values are shown as a measure of significance; P values <.05 are statistically significant. Cramer’s V was used to calculate the effect size (<0.05 no effect; 0.06-0.15 small effect, 0.16-0.30 medium effect, >0.30 large effect). The activity launched on November 19, 2015 and data were collected through January 29, 2016. Participants who answered all pre-/post questions during this time period were included in analyses.


Baseline knowledge was higher among D/E compared to PCPs:

  • 30% of PCPs compared to 49% of D/Es recognized the effect of an SGLT2 inhibitor on body weight

  • 42% of PCPs compared to 69% of D/Es recognized recent clinical trial data on cardiovascular outcomes for an SGLT2 inhibitor

Significant overall improvements were seen for both the PCPs (n = 267; P < .05; medium effect V= 0.215) and D/Es (n = 122; P < .05; small effect V= 0.131) as a result of participation in the CME activity. Specific areas of improvements include:

  • 36% more PCPs (P < .05) and 29% more D/Es (P <.05) correctly identified the effect of an SGLT2 inhibitor on body weight

  • 32% more PCPs (P < .05) and 24% more D/Es (P <.05) correctly translated recent clinical trial data into appropriate patient education point related to genital mycotic infections

Post-assessment scores reveal continued educational gaps:

  • 32% of PCPs compared to 28% of D/Es failed to identify appropriate patient education point related to genital mycotic infections

  • 43% of PCPs compared to 26% of D/Es failed to recognize recent cardiovascular outcomes clinical trial data for an SGLT2 inhibitor


This study demonstrates the success of a targeted educational intervention on improving knowledge and competence of PCPs and D/Es regarding new data related to SGLT2 inhibitors. Although baseline knowledge was lower among PCPs compared to D/Es, demonstrating a higher need for more foundational education for PCPs, both groups showed significant improvements in knowledge as a result of the education. Additional education on clinical trial data related to SGLT2 inhibitors is needed for both PCPs and D/Es given the low post-assessment scores.


Nothing to Disclose: AL, ML, AL